LeMaitre Vascular Inc (LMAT) stock
Close on Nov 18, 2026Market cap $1.73BP/E 26.5Yield 1.06%
Earnings
LeMaitre Vascular's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of LeMaitre Vascular's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | $68.00M | +11.5% | $0.65 | $0.65 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026after the close | $70.40M | +9.7% | $0.74 | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026after the close | $66.60M | +11.2% | $0.68 | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026after the close | $64.50M | +15.8% | $0.68 | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $61.00M | +11.3% | $0.75 | $0.62 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025after the close | $64.20M | +15.1% | $0.60 | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 1, 2025after the close | $59.87M | +11.9% | $0.48 | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025after the close | $55.70M | +13.9% | $0.49 | $0.49 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 31, 2024after the close | $54.80M | +15.6% | $0.49 | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024after the close | $55.80M | +11.4% | $0.52 | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024after the close | $53.50M | +13.6% | $0.44 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024after the close | $48.90M | +19.3% | $0.38 | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 1, 2023after the close | $47.40M | +21.5% | $0.33 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 1, 2023after the close | $50.10M | +19.0% | $0.36 | $0.37 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 2, 2023after the close | $47.10M | +18.9% | $0.27 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023during market hours | $41.00M | +3.8% | $0.25 | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 27, 2022after the close | $39.00M | +1.6% | $0.25 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 28, 2022after the close | $42.10M | – | $0.16 | $0.29 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 28, 2022after the close | $39.60M | – | $0.27 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022after the close | $39.50M | – | $0.28 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 28, 2021after the close | $38.40M | – | $0.30 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 13, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 29, 2021after the close | – | – | – | – | Release |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021after the close | – | – | – | – | Release |
| Q3 FY2020ended Sep 30, 2020 | Oct 29, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
LeMaitre Vascular's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| SalesGAAP | Q4 FY2026 | $69.90M – $71.90M | – | New | Nov 4, 2026 |
| Sales | Q4 FY2026 | $71.10M – $73.10M | – | New | Aug 4, 2026 |
| Gross MarginGAAP | Q4 FY2026 | 72.1% | – | New | Nov 4, 2026 |
| Op. IncomeGAAP | Q4 FY2026 | $18.80M – $20.20M | – | New | Nov 4, 2026 |
| Op. Income | Q4 FY2026 | $19.80M – $21.20M | – | New | Aug 4, 2026 |
| Op. Margin (Mid)GAAP | Q4 FY2026 | 27% | – | New | Nov 4, 2026 |
| EPSGAAP | Q4 FY2026 | $0.70 – $0.75 | – | New | Nov 4, 2026 |
| EPS | Q4 FY2026 | $0.75 – $0.81 | – | New | Aug 4, 2026 |
| SalesGAAP | FY2026 | $274.80M – $276.80M | – | New | Nov 4, 2026 |
| Sales | FY2026 | $274.30M – $278.30M | $277.00M – $283.00M | Lowered | Aug 4, 2026 |
| Gross MarginGAAP | FY2026 | 72.1% | – | New | Nov 4, 2026 |
| Op. IncomeGAAP | FY2026 | $74.60M – $76.10M | – | New | Nov 4, 2026 |
| Op. Income | FY2026 | $75.30M – $78.20M | $77.60M – $82.00M | Lowered | Aug 4, 2026 |
| Op. Margin (Mid)GAAP | FY2026 | 27% | – | New | Nov 4, 2026 |
| EPSGAAP | FY2026 | $2.77 – $2.82 | – | New | Nov 4, 2026 |
| EPS | FY2026 | $2.84 – $2.94 | $2.93 – $3.08 | Lowered | Aug 4, 2026 |
Guidance vs results
The last range LeMaitre Vascular gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | EPS (GAAP) | $0.66 – $0.71 | $0.65 | Below range |
| Q3 FY2026 | Revenue | $66.30M – $68.30M | $68.00M | Within range |
| Q2 FY2026 | EPS (GAAP) | $0.79 – $0.84 | $0.74 | Below range |
| Q2 FY2026 | Revenue | $70.50M – $72.50M | $70.40M | Below range |
| Q1 FY2026 | EPS (GAAP) | $0.64 – $0.69 | $0.68 | Within range |
| Q1 FY2026 | Revenue | $65.60M – $67.60M | $66.60M | Within range |
| FY2025 | EPS (GAAP) | $2.48 – $2.53 | $2.51Σ4Q | Within range |
| FY2025 | Revenue | $247.00M – $249.00M | $249.57MΣ4Q | Above range |
| Q4 FY2025 | EPS (GAAP) | $0.64 – $0.69 | $0.68 | Within range |
| Q4 FY2025 | Revenue | $61.80M – $63.80M | $64.50M | Above range |
| Q3 FY2025 | EPS (GAAP) | $0.54 – $0.59 | $0.75 | Above range |
| Q3 FY2025 | Revenue | $61.20M – $63.20M | $61.00M | Below range |
| Q2 FY2025 | EPS (GAAP) | $0.55 – $0.59 | $0.60 | Above range |
| Q2 FY2025 | Revenue | $61.50M – $63.50M | $64.20M | Above range |
| Q2 FY2025 | Revenue growth | +12% | +15.05% | Above range |
| Q1 FY2025 | EPS (GAAP) | $0.48 – $0.53 | $0.48 | Within range |
| Q1 FY2025 | Revenue | $56.70M – $58.70M | $59.87M | Above range |
| Q3 FY2024 | EPS (GAAP) | $0.42 – $0.46 | $0.49 | Above range |
| Q3 FY2024 | Revenue | $52.70M – $54.70M | $54.80M | Above range |
| Q2 FY2024 | EPS (GAAP) | $0.45 – $0.50 | $0.52 | Above range |
| Q2 FY2024 | Revenue | $53.70M – $56.10M | $55.80M | Within range |
| Q1 FY2024 | EPS (GAAP) | $0.36 – $0.41 | $0.44 | Above range |
| Q1 FY2024 | Revenue | $50.50M – $52.90M | $53.50M | Above range |
| Q4 FY2023 | EPS (GAAP) | $0.34 – $0.38 | $0.38 | Within range |
| Q4 FY2023 | Revenue | $48.00M – $50.00M | $48.90M | Within range |
| Q3 FY2023 | EPS (GAAP) | $0.28 – $0.33 | $0.33 | Within range |
| Q3 FY2023 | Revenue | $46.50M – $48.90M | $47.40M | Within range |
| Q2 FY2023 | EPS (GAAP) | $0.30 – $0.35 | $0.36 | Above range |
| Q2 FY2023 | Revenue | $47.10M – $49.50M | $50.10M | Above range |
| Q1 FY2023 | EPS (GAAP) | $0.22 – $0.27 | $0.27 | Within range |
| Q1 FY2023 | Revenue | $42.60M – $45.00M | $47.10M | Above range |
| Q4 FY2022 | EPS (GAAP) | $0.24 – $0.29 | $0.25 | Within range |
| Q4 FY2022 | Revenue | $39.80M – $42.20M | $41.00M | Within range |
| Q3 FY2022 | EPS (GAAP) | $0.24 – $0.29 | $0.25 | Within range |
| Q3 FY2022 | Revenue | $39.00M – $41.00M | $39.00M | Within range |
| Q2 FY2022 | EPS (GAAP) | $0.20 – $0.25 | $0.16 | Below range |
| Q2 FY2022 | Revenue | $40.10M – $42.10M | $42.10M | Within range |
| Q1 FY2022 | EPS (GAAP) | $0.26 – $0.30 | $0.27 | Within range |
| Q1 FY2022 | Revenue | $37.70M – $39.70M | $39.60M | Within range |
| Q4 FY2021 | EPS (GAAP) | $0.29 – $0.34 | $0.28 | Below range |
| Q4 FY2021 | Revenue | $39.00M – $41.00M | $39.50M | Within range |
Guidance history
Every forecast LeMaitre Vascular put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | EPS | FY2026 | $2.77 – $2.82 | New |
| Nov 4, 2026 | EPS | Q4 FY2026 | $0.70 – $0.75 | New |
| Nov 4, 2026 | Gross Margin | Q4 FY2026 | 72.1% | New |
| Nov 4, 2026 | Gross Margin | FY2026 | 72.1% | New |
| Nov 4, 2026 | Op. Income | Q4 FY2026 | $18.80M – $20.20M | New |
| Nov 4, 2026 | Op. Income | FY2026 | $74.60M – $76.10M | New |
| Nov 4, 2026 | Op. Margin (Mid) | Q4 FY2026 | 27% | New |
| Nov 4, 2026 | Op. Margin (Mid) | FY2026 | 27% | New |
| Nov 4, 2026 | Sales | Q4 FY2026 | $69.90M – $71.90M | New |
| Nov 4, 2026 | Sales | FY2026 | $274.80M – $276.80M | New |
| Aug 4, 2026 | EPS | FY2026 | $2.84 – $2.94 | Lowered |
| Aug 4, 2026 | EPS | Q3 FY2026 | $0.66 – $0.71 | New |
| Aug 4, 2026 | EPS | Q4 FY2026 | $0.75 – $0.81 | New |
| Aug 4, 2026 | Op. Income | FY2026 | $75.30M – $78.20M | Lowered |
| Aug 4, 2026 | Op. Income | Q3 FY2026 | $17.30M – $18.80M | New |
| Aug 4, 2026 | Op. Income | Q4 FY2026 | $19.80M – $21.20M | New |
| Aug 4, 2026 | Sales | FY2026 | $274.30M – $278.30M | Lowered |
| Aug 4, 2026 | Sales | Q3 FY2026 | $66.30M – $68.30M | New |
| Aug 4, 2026 | Sales | Q4 FY2026 | $71.10M – $73.10M | New |
| May 5, 2026 | EPS | Q2 FY2026 | $0.79 – $0.84 | New |
| May 5, 2026 | EPS | FY2026 | $2.93 – $3.08 | Raised |
| May 5, 2026 | Op. Income | FY2026 | $77.60M – $82.00M | Raised |
| May 5, 2026 | Op. Income | Q2 FY2026 | $20.80M – $22.30M | New |
| May 5, 2026 | Sales | FY2026 | $277.00M – $283.00M | Narrowed |
| May 5, 2026 | Sales | Q2 FY2026 | $70.50M – $72.50M | New |
| Feb 25, 2026 | EPS | FY2026 | $2.81 – $3.01 | New |
| Feb 25, 2026 | EPS | Q1 FY2026 | $0.64 – $0.69 | New |
| Feb 25, 2026 | Op. Income | FY2026 | $75.00M – $80.70M | New |
| Feb 25, 2026 | Op. Income | Q1 FY2026 | $16.70M – $18.10M | New |
| Feb 25, 2026 | Sales | FY2026 | $276.00M – $284.00M | New |
| Feb 25, 2026 | Sales | Q1 FY2026 | $65.60M – $67.60M | New |
| Nov 6, 2025 | EPS | FY2025 | $2.37 | New |
| Nov 6, 2025 | EPS | FY2025 | $2.48 – $2.53 | New |
| Nov 6, 2025 | EPS | Q4 FY2025 | $0.64 – $0.69 | New |
| Nov 6, 2025 | Gross Margin | FY2025 | 70.3% | New |
| Nov 6, 2025 | Op. Income | Q4 FY2025 | $17.30M – $18.70M | New |
| Nov 6, 2025 | Op. Income | FY2025 | $66.40M – $67.80M | New |
| Nov 6, 2025 | Op. Income | FY2025 | $63.70M | New |
| Nov 6, 2025 | Op. Margin (Mid) | FY2025 | 26% | New |
| Nov 6, 2025 | Sales | Q4 FY2025 | $61.80M – $63.80M | New |
| Nov 6, 2025 | Sales | FY2025 | $247.00M – $249.00M | New |
| Aug 5, 2025 | EPS | Q3 FY2025 | $0.54 – $0.59 | New |
| Aug 5, 2025 | EPS | FY2025 | $2.23 – $2.37 | Raised |
| Aug 5, 2025 | Op. Income | Q3 FY2025 | $14.40M – $15.80M | New |
| Aug 5, 2025 | Op. Income | FY2025 | $58.80M – $63.00M | Raised |
| Aug 5, 2025 | Sales | Q3 FY2025 | $61.20M – $63.20M | New |
| Aug 5, 2025 | Sales | FY2025 | $248.00M – $254.00M | Raised |
| May 1, 2025 | EPS | Q2 FY2025 | $0.55 – $0.59 | New |
| May 1, 2025 | EPS | FY2025 | $2.07 – $2.24 | Lowered |
| May 1, 2025 | Op. Income | Q2 FY2025 | $14.60M – $16.00M | New |
| May 1, 2025 | Op. Income | FY2025 | $55.10M – $60.30M | Lowered |
| May 1, 2025 | Adjusted projected net sales increase | Q2 FY2025 | +12% | New |
| May 1, 2025 | Sales | Q2 FY2025 | $61.50M – $63.50M | New |
| May 1, 2025 | organic sales guidance | FY2025 | +13% | New |
| May 1, 2025 | Sales | FY2025 | $242.00M – $249.00M | Raised |
| Feb 27, 2025 | EPS | Q1 FY2025 | $0.48 – $0.53 | New |
| Feb 27, 2025 | EPS | FY2025 | $2.15 – $2.32 | New |
| Feb 27, 2025 | Op. Income | Q1 FY2025 | $12.30M – $13.70M | New |
| Feb 27, 2025 | Op. Income | FY2025 | $57.30M – $62.40M | New |
| Feb 27, 2025 | Sales | Q1 FY2025 | $56.70M – $58.70M | New |
| Feb 27, 2025 | Sales | FY2025 | $235.40M – $242.80M | New |
| Aug 1, 2024 | EPS | FY2024 | $1.82 – $1.91 | Raised |
| Aug 1, 2024 | EPS | Q3 FY2024 | $0.42 – $0.46 | New |
| Aug 1, 2024 | Op. Income | FY2024 | $49.70M – $52.50M | Raised |
| Aug 1, 2024 | Op. Income | Q3 FY2024 | $11.30M – $12.70M | New |
| Aug 1, 2024 | Sales | Q3 FY2024 | $52.70M – $54.70M | New |
| Aug 1, 2024 | Sales | FY2024 | $216.80M – $220.80M | Raised |
| May 2, 2024 | EPS | Q2 FY2024 | $0.45 – $0.50 | New |
| May 2, 2024 | EPS | FY2024 | $1.73 – $1.84 | Raised |
| May 2, 2024 | Op. Income | FY2024 | $46.70M – $49.80M | Raised |
| May 2, 2024 | Op. Income | Q2 FY2024 | $12.00M – $13.70M | New |
| May 2, 2024 | Sales | Q2 FY2024 | $53.70M – $56.10M | New |
| May 2, 2024 | Sales | FY2024 | $212.70M – $217.30M | Raised |
| Feb 27, 2024 | EPS | Q1 FY2024 | $0.36 – $0.41 | New |
| Feb 27, 2024 | EPS | FY2024 | $1.60 – $1.71 | New |
| Feb 27, 2024 | Op. Income | FY2024 | $43.40M – $46.50M | New |
| Feb 27, 2024 | Op. Income | Q1 FY2024 | $9.70M – $11.30M | New |
| Feb 27, 2024 | Sales | Q1 FY2024 | $50.50M – $52.90M | New |
| Feb 27, 2024 | Sales | FY2024 | $209.70M – $214.30M | New |
| Nov 1, 2023 | EPS Ex-Special* | FY2023 | $1.32 – $1.36 | Raised |
| Nov 1, 2023 | EPS | Q4 FY2023 | $0.34 – $0.38 | Raised |
| Nov 1, 2023 | EPS | FY2023 | $1.30 – $1.35 | Raised |
| Nov 1, 2023 | Op. Inc. Ex-Special* | FY2023 | $36.40M – $37.70M | Raised |
| Nov 1, 2023 | Op. Inc. | FY2023 | $35.90M – $37.20M | Raised |
| Nov 1, 2023 | Op. Inc. | Q4 FY2023 | $9.40M – $10.70M | Raised |
| Nov 1, 2023 | Sales | FY2023 | $192.60M – $194.60M | Lowered |
| Nov 1, 2023 | Sales | Q4 FY2023 | $48.00M – $50.00M | Lowered |
| Aug 1, 2023 | EPS Ex-Special* | FY2023 | $1.25 – $1.35 | Raised |
| Aug 1, 2023 | EPS | FY2023 | $1.23 – $1.34 | Raised |
| Aug 1, 2023 | EPS | Q4 FY2023 | $0.32 – $0.38 | New |
| Aug 1, 2023 | EPS | Q3 FY2023 | $0.28 – $0.33 | New |
| Aug 1, 2023 | Op. Inc. Ex-Special* | FY2023 | $33.90M – $37.00M | Raised |
| Aug 1, 2023 | Op. Inc. | FY2023 | $33.40M – $36.50M | Raised |
| Aug 1, 2023 | Op. Inc. | Q4 FY2023 | $8.70M – $10.20M | New |
| Aug 1, 2023 | Op. Inc. | Q3 FY2023 | $7.40M – $8.90M | New |
| Aug 1, 2023 | Sales | Q4 FY2023 | $49.30M – $51.70M | New |
| Aug 1, 2023 | Sales | FY2023 | $193.00M – $197.80M | Raised |
| Aug 1, 2023 | Sales | Q3 FY2023 | $46.50M – $48.90M | New |
| May 2, 2023 | EPS Ex-Special* | Q2 FY2023 | $0.30 – $0.35 | New |
| May 2, 2023 | EPS Ex-Special* | FY2023 | $1.15 – $1.28 | New |
| May 2, 2023 | EPS | Q2 FY2023 | $0.30 – $0.35 | New |
| May 2, 2023 | EPS | FY2023 | $1.14 – $1.27 | Raised |
| May 2, 2023 | Op. Income Ex-Special* | Q2 FY2023 | $8.00M – $9.60M | New |
| May 2, 2023 | Op. Income Ex-Special* | FY2023 | $32.00M – $35.90M | New |
| May 2, 2023 | Op. Income | FY2023 | $31.70M – $35.60M | Raised |
| May 2, 2023 | Op. Income | Q2 FY2023 | $8.00M – $9.60M | New |
| May 2, 2023 | Sales | FY2023 | $187.10M – $193.10M | Raised |
| May 2, 2023 | Sales | Q2 FY2023 | $47.10M – $49.50M | New |
| Feb 23, 2023 | EPS | Q1 FY2023 | $0.22 – $0.27 | New |
| Feb 23, 2023 | EPS | FY2023 | $1.11 – $1.20 | New |
| Feb 23, 2023 | Op. Income | FY2023 | $30.60M – $33.30M | New |
| Feb 23, 2023 | Op. Income | Q1 FY2023 | $6.00M – $7.50M | New |
| Feb 23, 2023 | Sales | FY2023 | $174.30M – $178.30M | New |
| Feb 23, 2023 | Sales | Q1 FY2023 | $42.60M – $45.00M | New |
| Oct 27, 2022 | EPS Ex-Spec. Charge | FY2022 | $1.02 – $1.08 | Lowered |
| Oct 27, 2022 | EPS | FY2022 | $0.91 – $0.97 | Lowered |
| Oct 27, 2022 | EPS | Q4 FY2022 | $0.24 – $0.29 | Lowered |
| Oct 27, 2022 | Op. Income Ex-Spec. Charge | FY2022 | $29.60M – $31.10M | Lowered |
| Oct 27, 2022 | Op. Income | Q4 FY2022 | $6.60M – $8.20M | Lowered |
| Oct 27, 2022 | Op. Income | FY2022 | $26.50M – $28.00M | Lowered |
| Oct 27, 2022 | Sales | Q4 FY2022 | $39.80M – $42.20M | Lowered |
| Oct 27, 2022 | Sales | FY2022 | $160.50M – $162.90M | Lowered |
| Jul 28, 2022 | EPS Ex-Spec. Charge | FY2022 | $1.14 – $1.19 | Lowered |
| Jul 28, 2022 | EPS | Q3 FY2022 | $0.24 – $0.29 | New |
| Jul 28, 2022 | EPS | FY2022 | $0.99 – $1.05 | Lowered |
| Jul 28, 2022 | EPS | Q4 FY2022 | $0.29 – $0.35 | New |
| Jul 28, 2022 | Op. Income Ex-Spec. Charge | FY2022 | $32.70M – $34.40M | Lowered |
| Jul 28, 2022 | Op. Income | Q3 FY2022 | $6.80M – $8.20M | New |
| Jul 28, 2022 | Op. Income | Q4 FY2022 | $8.50M – $9.90M | New |
| Jul 28, 2022 | Op. Income | FY2022 | $29.50M – $31.20M | Lowered |
| Jul 28, 2022 | Sales | FY2022 | $162.70M – $165.30M | Raised |
| Jul 28, 2022 | Sales | Q3 FY2022 | $39.00M – $41.00M | New |
| Jul 28, 2022 | Sales | Q4 FY2022 | $41.20M – $43.20M | New |
| Apr 28, 2022 | EPS Excluding Special Charges | FY2022 | $1.21 – $1.31 | New |
| Apr 28, 2022 | EPS Excluding Special Charges | Q2 FY2022 | $0.29 – $0.35 | New |
| Apr 28, 2022 | EPS | Q2 FY2022 | $0.20 – $0.25 | New |
| Apr 28, 2022 | EPS | FY2022 | $1.10 – $1.20 | Lowered |
| Apr 28, 2022 | Op. Income Excluding Special Charges | FY2022 | $34.50M – $37.10M | New |
| Apr 28, 2022 | Op. Income Excluding Special Charges | Q2 FY2022 | $8.30M – $9.60M | New |
| Apr 28, 2022 | Op. Income | FY2022 | $31.40M – $34.00M | Lowered |
| Apr 28, 2022 | Op. Income | Q2 FY2022 | $5.70M – $7.00M | New |
| Apr 28, 2022 | Sales | Q2 FY2022 | $40.10M – $42.10M | New |
| Apr 28, 2022 | Sales | FY2022 | $160.00M – $164.00M | Lowered |
| Feb 24, 2022 | EPS | Q1 FY2022 | $0.26 – $0.30 | New |
| Feb 24, 2022 | EPS | FY2022 | $1.35 – $1.45 | New |
| Feb 24, 2022 | Op. Income | Q1 FY2022 | $7.10M – $8.40M | New |
| Feb 24, 2022 | Op. Income | FY2022 | $38.50M – $41.10M | New |
| Feb 24, 2022 | Sales | FY2022 | $162.00M – $166.00M | New |
| Feb 24, 2022 | Sales | Q1 FY2022 | $37.70M – $39.70M | New |
| Oct 28, 2021 | EPS | FY2021 | $1.26 – $1.31 | New |
| Oct 28, 2021 | EPS | Q4 FY2021 | $0.29 – $0.34 | New |
| Oct 28, 2021 | Op. Income | FY2021 | $36.50M – $37.80M | New |
| Oct 28, 2021 | Op. Income | Q4 FY2021 | $8.30M – $9.70M | New |
| Oct 28, 2021 | Sales | FY2021 | $153.90M – $155.90M | New |
| Oct 28, 2021 | Sales | Q4 FY2021 | $39.00M – $41.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases LeMaitre Vascular filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?